NCT01624571View on ClinicalTrials.gov

Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO

PHASE2CompletedINTERVENTIONAL

Enrollment

147

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Colon Resection_large Interstinal Surgery

Interventions

DRUG

LD02GIFRO

comparison of different dosages of drug

Trial Locations (1)

138-736

Asan medical center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01624571 - Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO | Biotech Hunter | Biotech Hunter